

Please add [info@patentinsurance.com](mailto:info@patentinsurance.com) to your whitelist or address book so that you have no trouble receiving our future issues! The IPISC Newsletter is delivered free every month. Not receiving the newsletter? Please sign-up on our website, [www.patentinsurance.com](http://www.patentinsurance.com).

### [Happy Thanksgiving](#)

We would like to thank you for being a valued business partner, and we are grateful for the pleasure of serving you and your IP risk management needs.

---

### [IPISC announces IP insurance for the Retailing Industry](#)

Indemnity alone is not enough. Retailers are mistakenly assuming that their suppliers will handle the IP-related litigation and the associated expenses, but many times this is simply not the case. Companies operating in the retail space judiciously put indemnity language in their contracts requiring their suppliers to indemnify an IP infringement lawsuit; yet they are leaving themselves exposed by not requiring them to carry IP-specific defense insurance to fulfill their indemnity obligation.

---

### [Enterprise Risk Management & Intellectual Property Risk](#)

As part of constructing an Enterprise Risk Management (ERM) plan, it is important to understand and gauge what the company's intellectual property (IP) portfolio looks like, and address any concerns or potential exposures. IP can be a company's most valuable asset, yet it is often seriously neglected during risk management reviews. Companies who knowingly, or unknowingly, self-insure their IP portfolios are potentially risking the future viability of the company. Patent lawsuits in particular average \$2.8 million in litigation expenses alone, whether as a plaintiff or a defendant, when the amount in controversy is \$1 million - \$25 million.

---

### [Intellectual Property Insurance for the Biotechnology/Pharma Industries](#)

The Biotechnology industry ranks second, only behind the consumer products industry, in the number of patent cases filed from 1995-2012. Given the rise in non-practicing entity (NPE)-generated IP litigation, the Biotech industry has not been spared, as NPEs, more times than not, have successfully fared through IP litigation against practicing entities in this industry.

### **Follow us:**

